tc-99m gluceptate
Trade name: glucoscan
Small moleculeapprovedImaging agent
Approved
May 25, 1978
Clinical trial activity
0 trials · 0 clinical orgs · 4 marketing orgs
Phase 1
0
Phase 2
0
Phase 3
0
Phase 4
0
Timeline
1970s
- May 25, 1978
New England Nuclear — Earliest FDA Approval
- May 25, 1978
Bristol-Myers Squibb — Marketing Organization
- May 25, 1978
New England Nuclear — NDA Organization
- May 25, 1978
Bristol-Myers — Marketing Organization
- May 25, 1978
Bristol-Myers Squibb — NDA Secondary Org
1980s
- Jan 27, 1982
Draximage — NDA Secondary Org
Indications
Approved for
Mechanism of action
- contrast mediumRadiopaque
contrast medium radiopaque
Approval history
- approvedMay 25, 1978
Chemistry & pharmacology
- Mol. weight
- 324.18 g/mol
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Delivery
- Parenteral
- Availability
- Discontinued
- Imaging
- 99-technetium
Oral
No
Parenteral
Yes
Topical
No
Sources
- ChEMBLCHEMBL2110570 ↗
- ChEMBLCHEMBL1200639 ↗
Also known as
- glucoscan
- glucoscan
- glucoscan
- tc-99m gha
- tc-99m gluceptate
- tc-99m gluceptate
- tc-99m gluceptate
- tc-99m-gluceptate
- tc-99m glucoheptonate
- tc-99m-glucoheptonate
- technescan gluceptate
- technetium (99mtc) gluceptate
- technetium gluceptate
- technetium glucoheptonate
- technetium glucoscan
- technetium tc 99m gluceptate
- technetium tc 99m gluceptate
- technetium tc 99m gluceptate
- technetium tc-99m gluceptate kit
- technetium tc-99m gluceptate kit
- technetium tc 99m sodium gluceptate
- technetium tc 99m sodium gluceptate
- technetium tc 99m sodium gluceptate
Organizations
Marketing (5)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Bristol-Myers | For profit | MKTG | May 25, 1978 |
| Bristol-Myers Squibb | For profit | MKTG | May 25, 1978 |
| Bristol-Myers Squibb | For profit | NDA2 | May 25, 1978 |
| Draximage | For profit | NDA2 | Jan 27, 1982 |
| New England Nuclear | For profit | NDA | May 25, 1978 |